No abstract available.
Alendronate* ; Animals ; Diphosphonates ; Rats*

No abstract available.
Alendronate* ; Animals ; Rats*

No abstract available.
Alendronate ; Cell Proliferation

No abstract available.
Alendronate ; Humans ; Osteoporosis ; Vitamin D ; Vitamins

No abstract available.
Alendronate ; Humans ; Osteoporosis ; Vitamin D ; Vitamins

PURPOSE: Alendronate has been proposed as a local and systemic drug treatment used as an adjunct to scaling and root planing (SRP) for the treatment of periodontitis. However, its effectiveness has yet to be conclusively established. The purpose of the present meta-analysis was to assess the effectiveness of SRP with alendronate on periodontitis compared to SRP alone. METHODS: Five electronic databases were used by 2 independent reviewers to identify relevant articles from the earliest records up to September 2016. Randomized controlled trials (RCTs) comparing SRP with alendronate to SRP with placebo in the treatment of periodontitis were included. The outcome measures were changes in bone defect fill, probing depth (PD), and clinical attachment level (CAL) from baseline to 6 months. A fixed-effect or random-effect model was used to pool the extracted data, as appropriate. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the Cochrane χ² and I2 tests. RESULTS: After the selection process, 8 articles were included in the meta-analysis. Compared with SRP alone, the adjunctive mean benefits of locally delivered alendronate were 38.25% for bone defect fill increase (95% CI=33.05–43.45; P<0.001; I²=94.0%), 2.29 mm for PD reduction (95% CI=2.07–2.52 mm; P<0.001; I²=0.0%) and 1.92 mm for CAL gain (95% CI=1.55–2.30 mm; P<0.001; I²=66.0%). In addition, systemically administered alendronate with SRP significantly reduced PD by 0.36 mm (95% CI=0.18–0.55 mm; P<0.001; I²=0.0%) and increased CAL by 0.39 mm (95% CI=0.11–0.68 mm; P=0.006; I²=6.0%). CONCLUSIONS: The collective evidence regarding the adjunctive use of alendronate locally and systemically with SRP indicates that the combined treatment can improve the efficacy of non-surgical periodontal therapy on increasing CAL and bone defect fill and reducing PD. However, precautions must be exercised in interpreting these results, and multicenter studies evaluating this specific application should be carried out.
Alendronate* ; Outcome Assessment (Health Care) ; Periodontitis* ; Population Characteristics ; Root Planing*

OBJECTIVES: To evaluate the effect of postmenopausal hormone therapy alone or in combination with bisphosphonate on bone mineral density (BMD) in postmenopausal women. METHODS: One hundred three women diagnosed with low BMD in postmenopausal women were included in this study. All patients were classified into two groups; oarl hormone therpy alone (Group I) or with alendronate (Group II), given for 12 months. Dual energy X-ray absorptiometry was used to measure BMD before and after 12 months of treatment. RESULTS: In all groups, significant increase in bone density measurements were seen at 12 months of treatment. The BMD of lumbar spine more increased significantly in Group II than Group I. CONCLUSIONS: Postmenopausal hormone therapy is effective in osteopenic and osteoporotic women. However, the combined treatment with hormone therapy and bisphophonate is more effective in postmenopausal women with low BMD.
Absorptiometry, Photon ; Alendronate ; Bone Density ; Female ; Humans ; Menopause ; Spine

PURPOSE: To evaluate the changes in bone mineral density (BMD) after alendronate intake and to determine the side effects and patient compliance. MATERIALS AND METHODS: Two hundred twelve patients with osteoporosis were treated with alendronate. One hundred sixty-two patients were excluded because of early discontinuation. Thus, 50 patients were included in the analysis. RESULTS: The annual increase in BMD in patients taking alendronate was 7.2% (1st year), 3.4%, 2.0%, and 0.9% (4th year) in the L-spine, and 2.2%, 1.5%, -0.9%, and 0.9% in the femur. The changes in BMD of patients< 60 years of age were 2.1% in the L-spine and 3.4% in the femur. The BMD of patients between 60 and 69 years of age increased 6.3% and 0.5% in the L-spine and femur, respectively, and the BMD of patients >70 of age were 2.9% and 1.2% in the L-spine and femur, respectively. The BMD changes in patients with a T-score< -4.0 were 7.0% (L-spine) and 1.2% (femur), the BMD changes in patients with a T-score between -3.0 and -3.9 were 5.3% and 0.2% for the Lspine and femur, respectively, and the BMD changes in patients with a T-score >3.0 were 2.5% and 3.1% for the Lspine and femur, respectively. The reasons for early discontinuation of alendronate were difficulty in intake, economic reasons, and adverse events. CONCLUSION: The BMD changes were greater in the L-spine than the femu in alendronate users. At the first year, the changes in BMD was greatest. There was no significant difference in BMD change according to age. In the Lspine, however, BMD changes were greater in the group with lower T-scores. The early discontinuance rate was 74%, and the adverse events rate was 19.8%.
Alendronate ; Bone Density ; Femur ; Humans ; Osteoporosis ; Patient Compliance

OBJECTIVE: To evaluate the effects of estrogen replacement therapy and pamidronate on the bone metabolism in the postmenopausal women. METHODS: This prospective randomized clinical trial examined the effects of oral pamidronate and conjugated equine estrogen, in combination and seperately, on biochemical markers of bone turnover in 140 women with low bone mass. Treatment included pamidronate (group I, n=50), or conjugated equine estrogen (group II, n=50), conjugated equine estrogen plus alendronate (group III, n=40) for 12 months. Biochemical markers of bone turnover were also measured at months 6 and 12 months. RESULTS: Serum osteocalcin and urinary deoxypyridinoline in Group I, Group II and Group III decreased signifiantly at 12 months of treatment (p<0.05). But total alkaline phosphatase decreased significantly during the treatment in Group III, but not in Group I and Group II. CONCLUSION: The combined treatment with pamidronate and conjugated equine estrogen is more effective in postmenopausal women with osteoporosis by decreasing bone biochemical markers.
Alendronate ; Alkaline Phosphatase ; Biomarkers ; Estrogen Replacement Therapy* ; Estrogens* ; Female ; Humans ; Metabolism* ; Osteocalcin ; Osteoporosis ; Postmenopause ; Prospective Studies

PURPOSE: The decrease in bone mineral density (BMD) is a major complication after kidney transplantation. This was reported to occur preferentially during the first 6 months. However, the treatment and prevention strategies against a decline of BMD are not yet clear. METHODS: The data on the pre-transplant baseline and post-transplant 1 year BMD were archived and retrieved in 125 renal transplant recipients. The post-transplant changes of the BMD were compared by the baseline status of the BMD and the types of anti-osteoporosis treatment either with a vitamin D agent (alfacalcidiol) (n=18) or alendronate (n=21). Anti-osteoporosis treatment began within 30 days after transplantation, with an oral administration of 0.5 mcg/day vitamin D or 70 mg/week alendronate, and maintained until 1 year after transplantation. RESULTS: Regardless the degree of baseline BMD status, each group (the control, vitamin D, or alendronate group) showed a significant and uniform decrease of BMD during the post-transplant 1 year. The mean change in the spine BMD in the control, vitamin D, and alendronate group was -7.1+/-7.5%, -3.3+/-7.4% and -2.6+/-6.5%, respectively. The femur BMD also changed -5.1+/-7.7%, 1.1+/-5.3% and -1.5+/-8.2%, respectively. The degree of BMD decrease in the treatment groups was significantly lower than that in the control (P=0.014 in spine, P=0.003 in femur). When the severely reduced baseline BMD (T-score of spine or femur < or =-1) subgroups were analysed separately, the treatment groups (-3.7+/-6.5% in vitamin D and -1.1+/-6.4% in alendronate group) showed a significantly less decrease in the spine BMD than the control (-8.2+/-6.2%)(P=0.036). The femur BMD also showed a less decrease in the BMD in the treatment group, but this was not statistically significant (P=0.234). There was no significant difference between the vitamin D and alendronate treatment groups. CONCLUSION: After renal transplantation, early administration of vitamin D or alendronate showed some benefit to reduce the post-transplant decrease of BMD in both spine and femur area.
Administration, Oral ; Alendronate* ; Bone Density* ; Femur ; Kidney Transplantation* ; Spine ; Transplantation ; Vitamin D* ; Vitamins*